vs
Side-by-side financial comparison of AbbVie (ABBV) and PACS Group, Inc. (PACS). Click either name above to swap in a different company.
AbbVie is the larger business by last-quarter revenue ($16.6B vs $1.4B, roughly 12.2× PACS Group, Inc.). AbbVie runs the higher net margin — 10.9% vs 4.4%, a 6.5% gap on every dollar of revenue. On growth, PACS Group, Inc. posted the faster year-over-year revenue change (18.4% vs 10.0%). Over the past eight quarters, PACS Group, Inc.'s revenue compounded faster (20.5% CAGR vs 16.2%).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
ABBV vs PACS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $16.6B | $1.4B |
| Net Profit | $1.8B | $59.7M |
| Gross Margin | 72.6% | — |
| Operating Margin | 27.3% | 7.0% |
| Net Margin | 10.9% | 4.4% |
| Revenue YoY | 10.0% | 18.4% |
| Net Profit YoY | 8354.5% | 3022.5% |
| EPS (diluted) | $1.02 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.6B | $1.4B | ||
| Q3 25 | $15.8B | $1.3B | ||
| Q2 25 | $15.4B | $1.3B | ||
| Q1 25 | $13.3B | $1.3B | ||
| Q4 24 | $15.1B | $1.1B | ||
| Q3 24 | $14.5B | $1.0B | ||
| Q2 24 | $14.5B | $981.4M | ||
| Q1 24 | $12.3B | $934.3M |
| Q4 25 | $1.8B | $59.7M | ||
| Q3 25 | $186.0M | $52.4M | ||
| Q2 25 | $938.0M | $51.0M | ||
| Q1 25 | $1.3B | $28.5M | ||
| Q4 24 | $-22.0M | $1.9M | ||
| Q3 24 | $1.6B | $15.6M | ||
| Q2 24 | $1.4B | $-10.9M | ||
| Q1 24 | $1.4B | $49.1M |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | 17.1% | ||
| Q2 24 | 70.9% | 22.3% | ||
| Q1 24 | 66.7% | 21.2% |
| Q4 25 | 27.3% | 7.0% | ||
| Q3 25 | 12.1% | 6.4% | ||
| Q2 25 | 31.7% | 6.2% | ||
| Q1 25 | 28.0% | 3.8% | ||
| Q4 24 | -9.9% | 1.7% | ||
| Q3 24 | 26.5% | 2.2% | ||
| Q2 24 | 27.6% | 0.1% | ||
| Q1 24 | 22.7% | 8.6% |
| Q4 25 | 10.9% | 4.4% | ||
| Q3 25 | 1.2% | 3.9% | ||
| Q2 25 | 6.1% | 3.9% | ||
| Q1 25 | 9.6% | 2.2% | ||
| Q4 24 | -0.1% | 0.2% | ||
| Q3 24 | 10.8% | 1.5% | ||
| Q2 24 | 9.5% | -1.1% | ||
| Q1 24 | 11.1% | 5.3% |
| Q4 25 | $1.02 | $0.42 | ||
| Q3 25 | $0.10 | $0.32 | ||
| Q2 25 | $0.52 | $0.31 | ||
| Q1 25 | $0.72 | $0.17 | ||
| Q4 24 | $-0.03 | $-0.03 | ||
| Q3 24 | $0.88 | $0.10 | ||
| Q2 24 | $0.77 | $-0.07 | ||
| Q1 24 | $0.77 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3B | $197.0M |
| Total DebtLower is stronger | $58.9B | $353.2M |
| Stockholders' EquityBook value | $-3.3B | $946.8M |
| Total Assets | $134.0B | $5.6B |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3B | $197.0M | ||
| Q3 25 | $5.7B | $355.7M | ||
| Q2 25 | $6.5B | $294.2M | ||
| Q1 25 | $5.2B | $287.5M | ||
| Q4 24 | $5.6B | $157.7M | ||
| Q3 24 | $7.3B | $49.5M | ||
| Q2 24 | $13.2B | $73.4M | ||
| Q1 24 | $18.1B | $81.2M |
| Q4 25 | $58.9B | $353.2M | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | $411.9M | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
| Q4 25 | $-3.3B | $946.8M | ||
| Q3 25 | $-2.6B | $871.3M | ||
| Q2 25 | $-183.0M | $806.8M | ||
| Q1 25 | $1.4B | $750.2M | ||
| Q4 24 | $3.3B | $709.6M | ||
| Q3 24 | $6.0B | $660.0M | ||
| Q2 24 | $6.8B | $572.1M | ||
| Q1 24 | $8.0B | $128.0M |
| Q4 25 | $134.0B | $5.6B | ||
| Q3 25 | $133.9B | $5.6B | ||
| Q2 25 | $137.2B | $5.5B | ||
| Q1 25 | $136.2B | $5.5B | ||
| Q4 24 | $135.2B | $5.2B | ||
| Q3 24 | $143.4B | $4.5B | ||
| Q2 24 | $141.9B | $3.9B | ||
| Q1 24 | $148.9B | $3.9B |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | 0.58× | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.2B | $-3.4M |
| Free Cash FlowOCF − Capex | $4.9B | — |
| FCF MarginFCF / Revenue | 29.4% | — |
| Capex IntensityCapex / Revenue | 2.0% | — |
| Cash ConversionOCF / Net Profit | 2.87× | -0.06× |
| TTM Free Cash FlowTrailing 4 quarters | $17.8B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.2B | $-3.4M | ||
| Q3 25 | $7.0B | $204.8M | ||
| Q2 25 | $5.2B | $52.6M | ||
| Q1 25 | $1.6B | $150.2M | ||
| Q4 24 | $7.0B | $64.6M | ||
| Q3 24 | $5.4B | $209.2M | ||
| Q2 24 | $2.3B | $34.8M | ||
| Q1 24 | $4.0B | $58.8M |
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $3.8B | — |
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | 31.3% | — |
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | 2.87× | -0.06× | ||
| Q3 25 | 37.76× | 3.91× | ||
| Q2 25 | 5.49× | 1.03× | ||
| Q1 25 | 1.27× | 5.28× | ||
| Q4 24 | — | 33.78× | ||
| Q3 24 | 3.49× | 13.39× | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | 1.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
